| 1 |
Mohamed MA, Bayoumy EM, Swailam MM, Allam AS. Assessment of carotid atherosclerosis in Egyptian chronic hepatitis C patients after treatment by direct-acting antiviral drugs. Egypt Liver Journal 2022;12:54. [DOI: 10.1186/s43066-022-00218-8] [Reference Citation Analysis]
|
| 2 |
Sheen YJ, Hsu CC, Kung PT, Chiu LT, Tsai WC. Impact of chronic hepatitis on cardiovascular events among type 2 diabetes patients in Taiwan pay-for-performance program. Sci Rep 2022;12:11720. [PMID: 35810252 DOI: 10.1038/s41598-022-15827-x] [Reference Citation Analysis]
|
| 3 |
Wang YK, Wang YW, Lu CL, Huang YH, Hou MC, Chang YL, Lee WP, Lan KH. Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol. Sci Rep 2022;12:9942. [PMID: 35705594 DOI: 10.1038/s41598-022-13657-5] [Reference Citation Analysis]
|
| 4 |
Dalbeni A, Villani R, Bevilacqua M, Sacco F, Faccincani D, Cattazzo F, Cavallone F, Mantovani A, Ceruti V, Ieluzzi D, Paon V, Mantovani A, Serviddio G, Sacerdoti D. Effects of direct-acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real-life Italian experience. J Dig Dis 2022;23:324-30. [PMID: 35700113 DOI: 10.1111/1751-2980.13103] [Reference Citation Analysis]
|
| 5 |
Freekh DA, Helmy MW, Said M, El-Khodary NM. The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection. Saudi Pharm J 2021;29:1120-8. [PMID: 34703365 DOI: 10.1016/j.jsps.2021.08.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 6 |
Wang YW, Lee WP, Huang YH, Hou MC, Lan KH. Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis. BMC Infect Dis 2021;21:984. [PMID: 34548026 DOI: 10.1186/s12879-021-06657-9] [Reference Citation Analysis]
|
| 7 |
Spaziante M, Taliani G, Marchetti G, Tavelli A, Lichtner M, Cingolani A, Cicalini S, Biliotti E, Girardi E, Antinori A, Puoti M, d'Arminio Monforte A, Cozzi-Lepri A. Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort Study. Viruses 2021;13:1402. [PMID: 34372608 DOI: 10.3390/v13071402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 8 |
Muñoz-Hernández R, Ampuero J, Millán R, Gil-Gómez A, Rojas Á, Macher HC, Gallego-Durán R, Gato S, Montero-Vallejo R, Rico MC, Maya-Miles D, Sánchez-Torrijos Y, Soria IC, Stiefel P, Romero-Gómez M. Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study. Clin Transl Gastroenterol 2020;11:e00203. [PMID: 32955194 DOI: 10.14309/ctg.0000000000000203] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 9 |
Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 10 |
Hsiao YH, Chen WM, Chang CH, Chen MY. Future outcomes and health needs of chronic hepatitis C patients after receiving antiviral therapy. J Adv Nurs 2021;77:3370-8. [PMID: 33818822 DOI: 10.1111/jan.14850] [Reference Citation Analysis]
|
| 11 |
Hino N, Sasaki R, Takahashi Y, Koike M, Fukushima M, Haraguchi M, Honda T, Miuma S, Ozawa E, Miyaaki H, Ichikawa T, Nakao K. Treatment of Hepatitis C Virus Infection with Direct-acting Antiviral Agents Elevates the Serum Small-dense Low-density Lipoprotein Cholesterol Level. Intern Med 2021;60:191-9. [PMID: 33456023 DOI: 10.2169/internalmedicine.5563-20] [Reference Citation Analysis]
|
| 12 |
Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Yamashima M, Yamamichi S, Koike M, Nakano Y, Honda T, Yajima H, Uehara R, Miyazaki O, Kuribayashi Y, Kira K, Taura N, Nakao K. Direct-acting Antivirals Improved the Quality of Life, Ameliorated Disease-related Symptoms, and Augmented Muscle Volume Three Years Later in Patients with Hepatitis C Virus. Intern Med 2020;59:2653-60. [PMID: 33132304 DOI: 10.2169/internalmedicine.5102-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 13 |
Akl EM, Salah AA. Effect of new oral direct acting antiviral therapy on sexual function in male patients with hepatitis C virus. Andrologia 2020;52:e13835. [PMID: 33070383 DOI: 10.1111/and.13835] [Reference Citation Analysis]
|
| 14 |
Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. Journal of the Formosan Medical Association 2020;119:1019-40. [DOI: 10.1016/j.jfma.2020.04.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 15 |
Huang CF, Yu ML. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy. Clin Mol Hepatol 2020;26:251-60. [PMID: 32188235 DOI: 10.3350/cmh.2020.0018] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 16 |
Wang CC, Cheng PN, Kao JH. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther 2020;51:216-30. [PMID: 31746482 DOI: 10.1111/apt.15575] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 13.3] [Reference Citation Analysis]
|
